Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders

How Long is Long Enough?

Elizabeth E. Hathaway, John T. Walkup, Jeffrey R. Strawn*

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to both psychotherapeutic and psychopharmacologic treatment. However, there are limited data regarding the optimal treatment duration. This article systematically reviews guidelines and clinical trial data related to antidepressant treatment duration in pediatric patients with depressive and anxiety disorders. The extant literature suggests 9–12 months of antidepressant treatment for youth with major depressive disorder. For generalized, separation and social anxiety disorders, 6–9 months of antidepressant treatment may be sufficient, though many clinicians extend treatment to 12 months based on extrapolation of data from adults with anxiety disorders. Such extended treatment periods may decrease the risk of long-term morbidity and recurrence; however, the goal of treatment is ultimately remission, rather than duration of antidepressant pharmacotherapy. Moreover, while evidence-based guidelines represent a starting point, appropriate treatment duration varies and patient-specific response, psychological factors, and timing of discontinuation must be considered for individual pediatric patients.

Original languageEnglish (US)
Pages (from-to)31-39
Number of pages9
JournalCurrent Problems in Pediatric and Adolescent Health Care
Volume48
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Depressive Disorder
Anxiety Disorders
Antidepressive Agents
Pediatrics
Therapeutics
Separation Anxiety
Guidelines
Major Depressive Disorder
Primary Health Care
Clinical Trials
Psychology
Morbidity
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{0ac46015c82943beb39e3cbe5e626a54,
title = "Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough?",
abstract = "Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to both psychotherapeutic and psychopharmacologic treatment. However, there are limited data regarding the optimal treatment duration. This article systematically reviews guidelines and clinical trial data related to antidepressant treatment duration in pediatric patients with depressive and anxiety disorders. The extant literature suggests 9–12 months of antidepressant treatment for youth with major depressive disorder. For generalized, separation and social anxiety disorders, 6–9 months of antidepressant treatment may be sufficient, though many clinicians extend treatment to 12 months based on extrapolation of data from adults with anxiety disorders. Such extended treatment periods may decrease the risk of long-term morbidity and recurrence; however, the goal of treatment is ultimately remission, rather than duration of antidepressant pharmacotherapy. Moreover, while evidence-based guidelines represent a starting point, appropriate treatment duration varies and patient-specific response, psychological factors, and timing of discontinuation must be considered for individual pediatric patients.",
author = "Hathaway, {Elizabeth E.} and Walkup, {John T.} and Strawn, {Jeffrey R.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.cppeds.2017.12.002",
language = "English (US)",
volume = "48",
pages = "31--39",
journal = "Current Problems in Pediatric and Adolescent Health Care",
issn = "1538-5442",
publisher = "Mosby Inc.",
number = "2",

}

Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders : How Long is Long Enough? / Hathaway, Elizabeth E.; Walkup, John T.; Strawn, Jeffrey R.

In: Current Problems in Pediatric and Adolescent Health Care, Vol. 48, No. 2, 01.02.2018, p. 31-39.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders

T2 - How Long is Long Enough?

AU - Hathaway, Elizabeth E.

AU - Walkup, John T.

AU - Strawn, Jeffrey R.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to both psychotherapeutic and psychopharmacologic treatment. However, there are limited data regarding the optimal treatment duration. This article systematically reviews guidelines and clinical trial data related to antidepressant treatment duration in pediatric patients with depressive and anxiety disorders. The extant literature suggests 9–12 months of antidepressant treatment for youth with major depressive disorder. For generalized, separation and social anxiety disorders, 6–9 months of antidepressant treatment may be sufficient, though many clinicians extend treatment to 12 months based on extrapolation of data from adults with anxiety disorders. Such extended treatment periods may decrease the risk of long-term morbidity and recurrence; however, the goal of treatment is ultimately remission, rather than duration of antidepressant pharmacotherapy. Moreover, while evidence-based guidelines represent a starting point, appropriate treatment duration varies and patient-specific response, psychological factors, and timing of discontinuation must be considered for individual pediatric patients.

AB - Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to both psychotherapeutic and psychopharmacologic treatment. However, there are limited data regarding the optimal treatment duration. This article systematically reviews guidelines and clinical trial data related to antidepressant treatment duration in pediatric patients with depressive and anxiety disorders. The extant literature suggests 9–12 months of antidepressant treatment for youth with major depressive disorder. For generalized, separation and social anxiety disorders, 6–9 months of antidepressant treatment may be sufficient, though many clinicians extend treatment to 12 months based on extrapolation of data from adults with anxiety disorders. Such extended treatment periods may decrease the risk of long-term morbidity and recurrence; however, the goal of treatment is ultimately remission, rather than duration of antidepressant pharmacotherapy. Moreover, while evidence-based guidelines represent a starting point, appropriate treatment duration varies and patient-specific response, psychological factors, and timing of discontinuation must be considered for individual pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=85040336763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040336763&partnerID=8YFLogxK

U2 - 10.1016/j.cppeds.2017.12.002

DO - 10.1016/j.cppeds.2017.12.002

M3 - Article

VL - 48

SP - 31

EP - 39

JO - Current Problems in Pediatric and Adolescent Health Care

JF - Current Problems in Pediatric and Adolescent Health Care

SN - 1538-5442

IS - 2

ER -